BPC-157 TB-500 Stack – The Wolverine Stack Overview with Studies

Primary Benefits

• May accelerate healing of tendons, ligaments, and muscle tissue
• Supports angiogenesis and vascular repair
• Promotes re-epithelialization and wound closure
• May improve joint recovery and post-surgical outcomes
• Potential benefits for gut and inflammatory conditions (BPC-157)

Mechanism of Action

BPC-157

• A gastric-derived peptide shown in animal models to enhance angiogenesis, fibroblast migration, and growth factor signaling.
• Modulates the nitric oxide (NO) system and upregulates VEGF, improving blood flow to injured tissue.
• May enhance tendon fibroblast GH receptor expression in vitro.
• References:
  • Systematic review of BPC-157 in musculoskeletal healing (1993–2024)
  • Comprehensive review of pleiotropic effects
  • Wound healing and NO system interactions

TB-500 / Thymosin Beta-4 (Tβ4)

• Actin-binding peptide that promotes cell migration and angiogenesis.
• Enhances wound healing and tissue regeneration in multiple animal models.
• Human trials of topical Tβ4 (RGN-259) showed efficacy in ocular repair (dry eye, neurotrophic keratopathy).
• References:
  • Ligament healing in rat medial collateral ligament
  • Cutaneous wound healing in rats
  • RGN-259 in dry eye (phase II/III)
  • RGN-259 in neurotrophic keratopathy
  • Tβ4 in myocardial infarction repair

Dosing & Protocol
Subcutaneous (SQ) Injection

• Reconstitution:
  • BPC-157 – 5 mg vial → 2.5 ml bacteriostatic water
  • TB-500 – 5 mg vial → 2.5 ml bacteriostatic water
• Daily Dose:
  • BPC-157 – 250–500 mcg (12.5–25 units)
  • TB-500 – 200–400 mcg (10–20 units)
  • Peptides may be drawn into the same insulin syringe after separate reconstitution and injected together.
• Cycle:
  • 5 days on / 2 days off
  • Duration: 4–6 weeks
• Timing:
  • Take in the morning on an empty stomach, at least 30 minutes before eating.

Potential Side Effects

• Both peptides lack large-scale human safety trials.
• Reported side effects (rare, anecdotal): injection-site redness, mild nausea, appetite increase.
• Unknown long-term safety in humans.

Who Is This Stack For?

• Individuals exploring regenerative or performance-supportive peptides for joint, tendon, ligament, or soft tissue recovery.
• Athletes and biohackers refer to this as the “Wolverine Stack,” but note:
  • WADA Prohibited List: Both BPC-157 and TB-500 are banned for competitive athletes.
  • FDA Category 2 Substances: Neither peptide is approved; BPC-157 is specifically flagged as unsafe for compounding.

Notes

• Many TB-500 products are not full-length thymosin beta-4 but short fragments (e.g., LKKTETQ, aa 17–23). Research findings for Tβ4 may not fully translate to TB-500.
• Most evidence is from animal studies. Human data for BPC-157 are limited to retrospective knee pain case series and historical trials in ulcerative colitis.
• Tβ4 (as RGN-259) has clinical data in ocular conditions but not systemic musculoskeletal applications.
• Quality of commercially available peptides can vary significantly.

Disclaimer
This article is for educational purposes only and is not intended to replace medical advice. Always follow the guidance of your healthcare provider when using peptides. If you experience concerning symptoms or bruising that does not improve, seek professional medical care.